Takeda reports positive Phase III trial results of trelagliptin succinate to treat type 2 diabetes
Trelagliptin succinate is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor that controls blood glucose levels by selectively and continually inhibiting DPP-4, which helps in increasing insulin secretion depending on